Abstract:Introduction The majority of pancreatic cancer patients are diagnosed with advanced, metastatic disease. Biomarkers to detect pancreatic cancer at earlier stages could drastically improve the poor survival rates. Circulating tumor cells (CTCs) are tumor cells that disseminate or are shed into the vascular system and have been detected in patients at pre-malignant stages. However, detecting these rare cells accurately and reliably remains a challenge. The AccuCyte-CyteFinder system uses density-based enrichment of blood nucleated cells followed by detection of CTCs using fluorescence staining, whole slide scanning and automated image analysis. This study aimed to examine whether CTCs could be used to identify patients with pancreatic lesions likely to malignant. Methods 50 patients undergoing an endoscopic ultrasound procedure for a pancreatic mass were recruited at the Royal Prince Alfred Hospital, Sydney, Australia or Chris O'Brien Lifehouse, Sydney, Australia. Peripheral blood was collected prior to the procedure and processed for CTCs on the AccuCyte-CyteFinder platform using a CK+ EpCAM+ CD45- staining panel. Results 28% (14/50) were found to have an intraductal papillary mucinous neoplasm (IPMN), 10% (5/50) pancreatic ductal adenocarcinoma (PDAC), 6% (3/50) pancreatic neuroendocrine tumor (PNET), 42% (21/50) non-neoplastic pancreatic cyst, and 14% (7/50) normal (no mass found). CTCs were highest in the PDAC group with an average of 5 cells/ml, followed by the IPMN (3 cells/ml), pancreatic cyst (2.5 cells/ml), and PNET (0 cells/ml). 86% (12/14) of IPMN patients had detectable CTCs. 2 IPMN patients with CTC counts of more than 5 cells/ml resulted in a resected sample having high-grade dysplasia while 3 IPMN patients with no/low CTC counts resulted in a resected sample having low-grade dysplasia. There was no correlation with the size of the pancreatic mass and CTC number. Conclusions CTCs could be detected in patients with pre-malignant pancreatic cancer and could determine malignancy. CTCs could potentially be used to detect pancreatic cancer early however, larger patient numbers and longer follow-up are required to validate these findings. Citation Format: Dannel Yeo, Vera Klemm, Payal Saxena, Althea Bastian, Heidi Strauss, Charbel Sandroussi, Sara Wahlroos, Peter Grimison, John E.J. Rasko. Detection of circulating tumor cells for the early detection of pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C011.

A clinical study on determination of portal venous circulating tumor cells in patients with pancreatic cancer by endoscopic ultrasonography-guided fine needle aspiration

Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells As a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer.

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients

Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer.

Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma

Endoscopic Ultrasonography Guided Transgastric Trans-Portal System Fine Needle Aspiration for Diagnosing Pancreatic Head and Uncinate Process Malignancy.

Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer

Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma

Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma.

Distribution and Clinical Analysis of EpCAM+/Vimentin+ Circulating Tumor Cells in High-Risk Population and Cancer Patients

Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM‑independent enrichment and immunostaining‑fluorescence in situ hybridization

Correlation between the positive expression of circulating tumor cells and clinicopathological characteristics in well-differentiated nonfunctional pancreatic neuroendocrine tumors performed on CellSearch platform

Postoperative Metastasis Prediction Based on Portal Vein Circulating Tumor Cells Detected by Flow Cytometry in Periampullary or Pancreatic Cancer

Diagnostic value of endoscopic ultrasound guided fine needle aspiration in patients with pancreatic carcinoma

Gastric Cancer-Circulating Tumor Cells Isolation by Folic Acid Immunolipid Magnetic Beads and Clinical Application

Circulating tumor cells from peripheral blood in esophageal squamous cell carcinoma by negative selection and its clinical significance

Evaluation of EUS guided fine-needle aspiration in pancreatic space-occupying lesion

Application of Endoscopic Ultrasonography on Diagnosis of Vascular Involvement for Pancreatic Cancer

Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH

Abstract C011: Detection of circulating tumor cells for the early detection of pancreatic cancer